There is nervous control of the heart by ATP as a cotransmitter in sympathetic,
parasympathetic, and sensory-motor nerves, as well as in intracardiac neurons. Centers in …

ATP and its ultimate degradation product adenosine are potent extracellular signalling
molecules that elicit a variety of pathophysiological functions in the kidney through the …

Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …

Nucleotides are released from all cells through regulated pathways or as a result of plasma
membrane damage or cell death. Outside the cell, nucleotides act as signalling molecules …

The use of biomaterials in implanted medical devices remains hampered by platelet
adhesion and blood coagulation. Thrombus formation is a prevalent cause of failure of these …

Antiplatelet therapies are an essential tool to reduce the risk of developing clinically
apparent atherothrombotic disease and are a mainstay in the therapy of patients who have …

Mass cytometry (MC) uses mass spectrometry to simultaneously detect multiple metal-
conjugated antibodies on single cells, thereby enabling the detailed study of cellular …

Abstract Background Purinergic P2Y1 and P2Y12 receptors (P2Y1-R and P2Y12-R) are G
protein-coupled receptors (GPCR) activated by adenosine diphosphate (ADP) to mediate …

Antiplatelet therapy is a cornerstone in the secondary prophylaxis of adverse cardiovascular
events such as myocardial infarction and stroke. The cyclooxygenase inhibitor aspirin …

Antiplatelet therapy reduces atherothrombotic risk and has therefore become a cornerstone
in the treatment of cardiovascular disease. Aspirin, adenosine diphosphate P2Y12 receptor …